BioNTech SE

📍 Mainz, Germany🗓 Founded 2008👥 4,836 employees💰 Last funded Jan 2020
Biotechnology Research🌐 biontech.com
Website LinkedIn
BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Germany
1
Frequently asked questions
Who invested in BioNTech SE?
BioNTech SE has 2 investors on record on gritt.io.
When did BioNTech SE last raise funding?
The most recent investment in BioNTech SE recorded on gritt.io was in January 2020.
When was BioNTech SE founded?
BioNTech SE was founded in 2008.
What industry is BioNTech SE in?
BioNTech SE operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is BioNTech SE based?
BioNTech SE is headquartered in Mainz, Germany.